Future Research Priorities for Morbidity Control of Lymphedema

BACKGROUND: Innovation in the treatment of lower extremity lymphedema has received low priority from the governments and pharmaceutical industry. Advancing lymphedema is irreversible and initiates fibrosis in the dermis, reactive changes in the epidermis and subcutis. Most medical treatments offered...

詳細記述

保存先:
書誌詳細
出版年:Indian J Dermatol
主要な著者: Narahari, S R, Aggithaya, Madhur Guruprasad, Moffatt, Christine, Ryan, T J, Keeley, Vaughan, Vijaya, B, Rajendran, P, Karalam, S B, Rajagopala, S, Kumar, N K, Bose, K S, Sushma, K V
フォーマット: Artigo
言語:Inglês
出版事項: Medknow Publications & Media Pvt Ltd 2017
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5286751/
https://ncbi.nlm.nih.gov/pubmed/28216723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0019-5154.198039
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料